Chitrak (Plumbago zeylanica Linn.) is a strongly heating Ayurvedic root used chiefly when digestion is weak, appetite is poor, and a cold, heavy Kapha-Vata pattern predominates. The Ayurvedic Pharmacopoeia of India identifies the dried mature root as the official drug and assigns it Deepana (kindling digestive capacity), Pachana (supporting the processing of improperly digested material), Grahi, Shulahara, and Kapha-Vata-reducing actions.

Chitrak is not a casual “metabolism booster” or a universal remedy for bloating, weight gain, fatty liver, infection, or “detox.” Its sharp and hot profile, the presence of plumbagin, the pharmacopoeial requirement for Shodhana before use, animal reproductive findings, and extract-toxicity data all make practitioner-guided use important. Modern laboratory findings concern particular extracts or isolated plumbagin and should not be converted directly into claims for ordinary Chitrak powder or proprietary tablets.

Official Identity and Pharmacopoeial Standard

The Ayurvedic Pharmacopoeia of India, Part I, Volume I, defines Chitraka as the dried mature root of Plumbago zeylanica Linn., family Plumbaginaceae. The plant is described as a perennial, sub-scandent shrub found widely in India and also cultivated; the medicinal root is reddish to deep brown externally and acrid in taste.

Rasa Panchaka

The official Ayurvedic profile is distinctly pungent, light, dry, sharp, and heating. These attributes explain both its use in sluggish digestive states and the caution required when burning, inflammation, irritation, or bleeding tendencies predominate.

• Rasa (taste): Katu (pungent)
• Guna (qualities): Laghu (light), Ruksha (dry), Tikshna (sharp or penetrating)
• Virya (potency): Ushna (hot)
• Vipaka (post-digestive effect): Katu (pungent)
• Dosha action: Kaphavatahara, meaning that it reduces Kapha and Vata when appropriately selected

The Pharmacopoeia further lists Shothahara, Deepana, Grahi, Pachana, Arshohara, and Shulahara among its actions. These traditional terms should be interpreted within Ayurvedic diagnosis rather than translated into guaranteed biomedical outcomes.

Identity, Purity, and Strength

For authenticated root material, the Pharmacopoeia sets limits of not more than 3% foreign matter, 3% total ash, and 1% acid-insoluble ash, with not less than 12% alcohol-soluble extractive and 12% water-soluble extractive. These are quality-control standards for the crude drug; they do not by themselves prove that an unlicensed powder, online extract, or supplement has been correctly identified, purified, or manufactured.

Chitrak in the Ayurvedic Management of Agni

Agni is the Ayurvedic principle of digestion and transformation. Classical clinical reasoning distinguishes balanced, irregular, excessively sharp, and weak digestive states. Chitrak belongs primarily to the management of Mandagni, or weak digestive capacity, especially when coldness, heaviness, coating, reduced appetite, sluggishness after food, and Kapha-Vata features are present.

Deepana, Pachana, and Grahi

Deepana denotes the kindling of appetite and digestive capacity. Pachana denotes support for processing Ama, an Ayurvedic concept referring to material considered improperly digested or transformed. Grahi describes an absorbing or retaining action used in carefully selected bowel patterns. Because Chitrak combines all three actions in the official monograph, it may be chosen when weak digestion and an improperly processed bowel state occur together.

These actions are not interchangeable with increasing stomach acid, raising metabolic rate, “burning fat,” killing intestinal bacteria, or repairing intestinal permeability. Ayurveda selects the drug from the total pattern, including appetite, stool, tongue, pain, thirst, heat, strength, constitution, season, diet, and concurrent disease.

When the Profile Does Not Fit

Chitrak is poorly matched to a person who already has a sharp appetite accompanied by burning, sour regurgitation, marked thirst, mouth ulcers, inflamed gastric symptoms, heat intolerance, or bleeding. A patient may have bloating or heaviness for reasons other than Mandagni, including ulcer disease, gallbladder or pancreatic disease, infection, inflammatory bowel disease, medication effects, food intolerance, or obstruction. Persistent or severe symptoms require medical assessment rather than stronger digestive stimulants.

Traditional Actions and Uses Recorded in the API

The Pharmacopoeia lists Agnimandya, Grahani Roga, Arsha, Udara Shula, and Guda Shotha as therapeutic uses. In plain language, these refer to weak digestive function, a classical disorder centered on impaired digestion and bowel regulation, hemorrhoidal disease, abdominal colic, and swelling in the anal region.

Agnimandya and Grahani

In Ayurvedic practice, Chitrak is most directly associated with Agnimandya. Grahani treatment is broader than giving a hot herb: the clinician first distinguishes whether Ama is present, which dosha pattern dominates, whether stool is loose or retained, and whether the patient is depleted, inflamed, or strong enough for sharp medicines. Diet, meal timing, the accompanying vehicle, and supporting herbs are selected according to that assessment.

Arsha, Shula, and Guda Shotha

The API’s listing of Arsha, abdominal colic, and anal swelling reflects classical use, not a recommendation to self-treat rectal pain or bleeding. Fresh blood in stool, black stool, unexplained weight loss, fever, persistent vomiting, severe abdominal pain, a new anal mass, or altered bowel habits should be evaluated by a qualified healthcare provider. Chitrak’s hot and irritant profile may be unsuitable where active burning or bleeding dominates.

Phytochemistry: Plumbagin and the Limits of Extrapolation

The API identifies plumbagin as a constituent of Chitrak. PubChem describes plumbagin as 5-hydroxy-2-methyl-1,4-naphthoquinone with the molecular formula C₁₁H₈O₃. Analytical work has measured plumbagin in different parts of P. zeylanica, but plant part, source, processing, extraction solvent, and analytical method affect the measured amount.

No Universal Plumbagin Percentage

A single figure such as “0.5–1.0% plumbagin in every root” is not an official API specification and should not be treated as a universal composition. A crude root powder, a hydroalcoholic extract, a petroleum-ether extract, and isolated plumbagin are chemically and toxicologically different materials. Milligram-for-milligram comparisons between them are therefore misleading.

Cell and Animal Findings

Isolated plumbagin has been examined in cell systems and animal models. A cell-based study reported inhibition of the NF-κB activation pathway. A rat experiment reported effects on fructose-induced obesity and fatty-liver changes, and another diabetic-rat experiment reported increased GLUT4 expression and translocation. These experiments establish preclinical pharmacology for isolated plumbagin; they do not establish Chitrak root as a human treatment for obesity, nonalcoholic fatty liver disease, or diabetes.

An in-vitro antimicrobial paper found that plumbagin inhibited Staphylococcus aureus and Candida albicans under laboratory conditions. Such assays do not justify using Chitrak for bacterial overgrowth, candidiasis, or another diagnosed infection. Concentrations active in a laboratory system may not be safe, achievable, or effective in a person.

Weight, Fatty Liver, and Glucose Claims

The rat studies on obesity, fatty-liver changes, and glucose transport used isolated plumbagin under experimental conditions. They did not test ordinary Shodhita Chitrak root as a routine human supplement, and they do not establish a dose that is both effective and safe for people. The API monograph does not list obesity, diabetes, high cholesterol, or fatty liver among Chitrak’s therapeutic uses.

Chitrak should therefore not replace nutrition therapy, physical activity, metabolic assessment, liver evaluation, or prescribed treatment. Unexplained weight change, elevated glucose, abnormal liver enzymes, jaundice, persistent right-upper-abdominal pain, or suspected fatty liver needs standard medical evaluation. A practitioner may consider Ayurvedic digestive management as supportive care, but the purpose, preparation, and monitoring should be explicit.

Antioxidant and Anti-inflammatory Language

A published antioxidant study evaluated extracts of P. zeylanica and plumbagin in experimental systems. Other laboratory work has examined inflammatory signaling. These findings should be described by their test system rather than converted into broad claims that Chitrak “protects the liver,” “detoxifies the body,” “regenerates hepatocytes,” or protects the gastrointestinal lining at ordinary doses.

Classical Formulations Containing Chitrak

The API monograph names Chitrakadi Vati, Chitraka Haritaki, and Chitrakadi Churna as important formulations. Each formulation has its own composition, manufacturing process, dose, vehicle, and indication; the single-drug dose for Chitrak root cannot be transferred automatically to a compound medicine.

Chitrakadi Gutika or Chitrakadi Vati

Charaka Samhita, Chikitsa Sthana 15, describes Chitrakadi Gutika in the treatment of Grahani. The recipe combines Chitraka and Pippalimula with Yavakshara, Sarjikakshara, five salts, Trikatu, Hingu, Ajamoda, and Chavya, then triturates the powder with Matulunga or pomegranate juice to prepare pills. The text assigns the pills the functions of digesting Ama and quickly kindling Agni.

This is a saline, alkaline, pungent, and heating compound, not merely “Chitrak plus black pepper.” Its classical rationale is the coordinated Ayurvedic action of the full formula. Although piperine from black pepper has modern pharmacokinetic literature, that does not establish that Chitrakadi Vati universally increases the absorption of every medicine or that the combination is appropriate with prescription drugs.

Chitraka Haritaki

Chitraka Haritaki is an official semisolid formulation referenced in the Ayurvedic Formulary of India and standardized in the Ayurvedic Pharmacopoeia. Its composition is substantially more complex than a mixture of Chitrak, Haritaki, and jaggery: the official formulation begins with decoctions that include Chitraka and other drugs and is prepared as an avaleha. Product-specific sugar or honey content, the complete ingredient list, and the prescribed indication matter when selecting it.

Chitrakadi Churna

Chitrakadi Churna is named as an important Chitrak formulation in the single-drug monograph. Because similarly named powders may follow different textual or manufacturer references, the exact label, official reference, batch information, and directions should be checked rather than assuming one universal ingredient list or dose.

Agnitundi Vati

Agnitundi Vati is an AFI-listed pill preparation and is not interchangeable with Chitrakadi Vati. AFI-derived compositions include processed mineral ingredients as well as purified Vatsanabha and purified Vishamushti, alongside Chitrak and other digestive substances. It therefore belongs under the direct prescription of a qualified Ayurvedic physician and should not be selected from a general dosage table or used as an over-the-counter appetite pill.

Comparison of Common Chitrak Preparations

The safest comparison is based on dosage form, official status, and level of supervision rather than promotional claims or fixed treatment durations.

Choosing a Product and Reading the Label

Product identity matters because the pharmacopoeial drug is a defined plant part, while commercial products may be powders, tablets, semisolid avalehas, liquid extracts, or multi-ingredient pills. A label should be checked for the botanical name, plant part, complete ingredient list, classical or proprietary reference, manufacturer and licence details, batch number, expiry date, recommended dose, and warnings.

Single Herb Does Not Mean Simple Risk

A container labelled only “Chitrak powder” should not be assumed to meet the API monograph. The root must be authenticated, processed as required, and tested against applicable identity and purity standards. Concentrated extracts, tinctures of unknown strength, or products advertised by a plumbagin percentage require additional caution because their exposure may differ greatly from traditional powder.

Compound Medicines Require Full-Formula Review

For Chitrakadi Vati, Chitraka Haritaki, Agnitundi Vati, or another compound, safety depends on every ingredient. The multiple salts may matter for people following sodium restrictions, while alkaline ingredients may aggravate sensitive gastrointestinal symptoms. Sugars or honey may matter in diabetes, and purified mineral or poisonous ingredients require the exact authorized formulation and medical oversight. Substituting one brand, dosage form, or similarly named preparation for another can change the clinical risk.

Dosage, Timing, and Anupana

The API monograph gives 1–2 g of the drug in powder form as the dose for Chitrak root and immediately notes that Shodhana is to be performed before use. This pharmacopoeial range is not a personal prescription. Age, digestive strength, heat and bleeding symptoms, diagnosis, product identity, purification, co-ingredients, medicines, pregnancy status, liver and kidney function, and intended duration all affect whether the drug is suitable.

Why Fixed Internet Protocols Are Misleading

Rules such as “always take Chitrak before meals,” “increase the dose every three days,” or “taper it at the end” are not universal pharmacopoeial instructions. Classical timing and Anupana—the accompanying vehicle—depend on the formulation and clinical purpose. Warm water, buttermilk, ghee, honey, sour juice, or another vehicle may be specified in different contexts, and each changes suitability. People with diabetes or dietary restrictions also need the complete formulation and vehicle reviewed.

Shodhana Is Part of the Official Direction

The API specifically states that Chitrak should undergo Shodhana before use as described in its appendix. Shodhana is a defined Ayurvedic pharmaceutical process, not home washing, roasting, soaking at random, or mixing the powder with ghee. Raw root from a plant nursery, an unidentified market sample, or a homemade concentrated tincture should not be substituted for professionally processed material.

Safety: Irritation, Toxicity, Pregnancy, and Interactions

Chitrak requires a narrower safety approach than mild culinary digestives. The official hot and sharp profile is clinically relevant, while modern toxicology indicates that extraction method can greatly change risk. “Natural” and “classical” do not mean that every form, dose, duration, or patient is safe.

Extract Toxicity Is Dose- and Solvent-Dependent

In a Wistar-rat toxicity comparison, the petroleum-ether root extract had a reported oral LD₅₀ of 93.45 mg/kg, whereas acetone and hydroalcoholic extracts each had reported LD₅₀ values of 928.4 mg/kg. The more toxic petroleum-ether extract had higher plumbagin content. Subacute testing also identified changes in organ weights and laboratory markers in treated animals.

These figures describe specific experimental extracts in rats; they are not human dose limits and cannot be used to calculate a “safe” supplement dose. Their practical meaning is that concentration and solvent matter, and a high-plumbagin extract should not be treated as equivalent to Shodhita root powder or a standardized classical formulation.

Pregnancy and Reproductive Risk

Chitrak should be avoided during pregnancy. In a rat study, administration of P. zeylanica root powder during gestation was associated with abortion-related reproductive effects. Animal data do not define a safe human threshold, so using Chitrak to stimulate menstruation or attempting to terminate a pregnancy with it is unsafe and requires urgent medical guidance. Use while breastfeeding or when trying to conceive also warrants direct professional review.

Gastrointestinal and Pitta-Predominant Symptoms

Because the drug is Katu, Tikshna, Ruksha, and Ushna, self-use is inappropriate when there is active gastric or esophageal burning, suspected ulceration, recurrent vomiting, severe diarrhea, inflammatory bowel symptoms, rectal bleeding, or an unexplained abdominal condition. Stop the product and seek care if it produces marked burning, persistent pain, vomiting, diarrhea, rash, faintness, or bleeding.

Potential Herb-Drug Interactions

An in-vitro liver-microsome study found that plumbagin inhibited several cytochrome P450 enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4. This does not prove a clinical interaction at the doses delivered by every Chitrak product, but it supports caution with medicines that have narrow therapeutic margins or depend heavily on hepatic metabolism.

Anyone taking anticoagulants, antiplatelet drugs, diabetes medicines, anticonvulsants, immunosuppressants, cancer medicines, or multiple prescription drugs should have the complete product reviewed by a pharmacist or healthcare provider. The assessment must include every ingredient in a compound formulation, not only Chitrak.

People Who Should Not Self-Prescribe Chitrak

Professional evaluation is especially important for pregnant or breastfeeding patients, children, older or frail adults, people with active reflux or ulcer symptoms, unexplained bleeding, significant liver or kidney disease, chronic inflammatory gastrointestinal illness, and those using regular medicines. The presence of warning symptoms takes priority over an Ayurvedic trial.

What Modern Pharmacology Can Support

Modern publications support a limited and precise account: Chitrak contains plumbagin; isolated plumbagin has measurable activity in cell and animal systems; extraction changes exposure and toxicity; and clinically relevant interaction potential remains possible. These facts justify scientific interest and careful pharmacovigilance, not broad claims of proven weight loss, diabetes control, liver regeneration, infection treatment, or cancer therapy.

Human Clinical Literature

A 2024 publication described one patient with Mandagni who received Chitrakadi Vati together with Ekakala Bhojana, a one-meal-a-day regimen. Because it was a single case with a simultaneous dietary intervention, it cannot isolate the effect of the tablet or provide a controlled estimate of benefit. It is more accurate to treat it as a clinical description than as proof of a standard 14-day protocol for all patients.

Why Whole Formulations Still Need Their Own Data

A classical formula cannot be assumed to “buffer” plumbagin toxicity merely because it contains multiple ingredients. Processing, ingredient ratios, dose, contaminants, batch consistency, and the patient’s condition all influence safety. Conversely, findings from isolated plumbagin cannot be applied automatically to a properly manufactured formulation. Each preparation must be judged by its own official reference, quality standards, composition, and clinical context.

Responsible Use in Practice

A qualified practitioner should first establish that the pattern is truly Mandagni or another indication compatible with Chitrak, exclude urgent biomedical causes, and choose between diet, a milder digestive, purified single-drug Chitrak, or a compound formulation. Follow-up should review appetite, stool, pain, burning, hydration, weight change, concomitant medicines, and any new adverse symptom rather than continuing solely because a fixed course was advertised.

Diet, Routine, and Follow-Up

Ayurvedic management of weak digestion is not limited to a tablet. Meal quantity, regularity, food compatibility, chewing, sleep, activity, bowel pattern, and the presence of stress or illness can all alter digestive function. A strong Deepana-Pachana medicine cannot compensate safely for persistent overeating, irregular meals, alcohol excess, or an undiagnosed gastrointestinal disorder.

Monitoring the Response

A favorable response should not be judged only by feeling more heat or hunger. The practitioner should look for comfortable appetite, easier digestion, reduced heaviness, an appropriate stool pattern, stable hydration, and absence of burning, pain, bleeding, or constitutional depletion. If symptoms recur whenever the medicine is stopped, the diagnosis, diet, dose, product, and underlying medical causes should be reassessed rather than extending the course indefinitely.

Balanced Summary

Chitrak is an important but potent Ayurvedic root. Its verified official profile is Katu rasa, Laghu-Ruksha-Tikshna guna, Ushna virya, Katu vipaka, and Kapha-Vata-reducing action, with Deepana, Pachana, Grahi, Shulahara, and related traditional uses. The API identifies plumbagin, sets quality standards, gives a 1–2 g powder range, and requires Shodhana before use.

Its most defensible place is individualized Ayurvedic care for a suitable weak-digestion pattern, often through a correctly prepared classical formulation. It should not be marketed as a general metabolism enhancer, a stand-alone obesity or fatty-liver treatment, an antimicrobial substitute, or a do-it-yourself detoxifier. Pregnancy, active burning or bleeding symptoms, concentrated extracts, complex medicines, and formulations containing processed mineral or toxic ingredients require particular caution.

This article is for education only and does not replace diagnosis or treatment by a qualified Ayurvedic practitioner or licensed healthcare provider. Do not self-prescribe Chitrak, concentrated Plumbago extracts, isolated plumbagin, or formulations containing processed toxic or mineral ingredients.

References

1. Ayurvedic Pharmacopoeia of India
2. Physiological aspects of Agni (2010), PubMed Central
3. Charaka Samhita — Grahani Chikitsa
4. Ncismindia (ncismindia.org)
5. Dravyaguna notes
6. Ayurvedic Pharmacopoeia of India
7. Sahasrayogam (sahasrayogam.com)
8. Pubchem (pubchem.ncbi.nlm.nih.gov)
9. [Determination of plumbagin in different parts of Plumbago zeylanica by RP-HPLC] (2006), PubMed
10. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents (2006), PubMed
11. Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress (2019), PubMed
12. Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats (2012), PubMed
13. Antimicrobial activity in vitro of plumbagin isolated from Plumbago species (2003), PubMed
14. Antioxidant properties of Plumbago zeylanica, an Indian medicinal plant and its active ingredient, plumbagin (2004), PubMed
15. Comparative toxicity profiles of Plumbago zeylanica L. root petroleum ether, acetone and hydroalcoholic extracts in Wistar rats (2015), PubMed
16. Effect of Plumbago zeylanica root powder induced preimplantationary loss and abortion on uterine luminal proteins in albino rats (1991), PubMed
17. Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach (2016), PubMed
18. Jaims (jaims.in)
19. Comparative hepatoprotective activity of detoxified roots of Plumbago zeylanica L. and Plumbago rosea L. in Wistar rats (2021), PubMed Central

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.